{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060084","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.266285+00:00","generated_at":"2026-06-01T23:25:56.084263+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Renalytix enters $15M at-the-market equity offering with H.C. Wainwright","bullets":["Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.","Placement fee of 3% of gross sales; company reimburses certain agent expenses.","Agreement effective May 15, 2024; no obligation to sell any ADSs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060084","json":"https://secwatch.observer/filing/0000950170-24-060084.json","markdown":"https://secwatch.observer/filing/0000950170-24-060084.md","text":"https://secwatch.observer/filing/0000950170-24-060084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024060084/0000950170-24-060084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024060084/rnlx-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:25:56.084263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15248f6fee04b62b1321734e35f821a425507f0c","claim":"Renalytix plc entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $15 million (effective 2024-05-15).","evidence_excerpt":"On May 15, 2024, Renalytix plc (the “ Company ”) entered into an at the market offering agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (the “ Agent ”), pursuant to which the Company may issue and sell from time to time, at its option, the Company’s American Depositary Shares (the “ ADSs ”), each representing two ordinary shares (nominal value £0.0025 per share) of the Company, through or to the Agent, as sales agent and/or principal.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024060084/0000950170-24-060084-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"up to $15 million"},{"label":"Effective","value":"2024-05-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}